Sales 2025 by Business Segment

Sales 2025 by Geography

Historical Breakdown of Revenue by Business Segments

Operating Income: Breakdown by Business Segment

Breakdown by Business Segment (KRW)
Fiscal Period: December 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Biological Products

          

Biopharmaceutical

1,616B 1,937B 1,873B 6,070B 6,033B

D&A

174B 175B 195B 386B 253B

Operating Income

712B 618B 638B 1,199B 1,215B

Pharmaceutical Products

          

Chemical Drugs

557B 654B 501B 531B 557B

D&A

46.13B 51.1B 53.81B 35.52B 38.15B

Operating Income

57.49B 34.61B 27.86B 9.18B 23.73B

Other

3.05B 3.88B 5.14B 5.82B 6.74B

D&A

281M 297M 240M 256M 262M

Operating Income

224M 294M 454M 506M 86.19M

Intersectoral Insider Transaction Reconciliation

-264B -311B -203B -3,050B -2,434B

D&A

-320M -304M -3.1B -4.02B -3.56B

Operating Income

-17.06B -5.3B -15.2B -717B -70.39B

Geographical Revenue Distribution History

Geographical breakdown of sales (KRW)
Fiscal Period: December 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

South Korea

2,015B 2,324B 2,262B 4,184B 3,526B

Total Assets

2,160B 2,341B 14,258B 10,031B 10,183B

Europe

- - - 1,862B 2,145B

Total Assets

- - 185B 779B 798B

Total Assets

- - 3.48B - -

Total Assets

- - 1.72B - -

North America

- - - 168B 420B

Total Assets

- - 7.91B 3,964B 4,359B

Asia

76.42B 140B 117B 252B 344B

Total Assets

308B 300B 117B 117B 97.22B

Latin America

- - - - 162B

Total Assets

- - - 92.28B 93.53B

Central and South America

- - - 141B -

Americas

84.61B 131B - - -

Total Assets

209M - - - -

Overseas

- - - - -

Consolidation Adjustment

-264B -311B -203B -3,050B -2,434B

Total Assets

-5.98B -11.1B -22.06B -36.57B -49.84B